clinical 3,109 words KG: Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)
Contents

Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

Wikipedia

Related Hypotheses (28)

RNA Granule Nucleation Site Modulation
Score: 0.66
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.62
Synaptic Vesicle Tau Capture Inhibition
Score: 0.58
HSP90-Tau Disaggregation Complex Enhancement
Score: 0.57
Digital Twin-Guided Metabolic Reprogramming
Score: 0.55
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.54
Cryptic Exon Silencing Restoration
Score: 0.53
← Prevpg 2/2

Related Analyses (6)

Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed

Related Experiments (5)

ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Neural Stem Cell Therapy for Alzheimer's Disease
clinical · proposed · Score: 0.40

Knowledge Graph (2 edges)

Tricaprilin Phase 3 ALTER-AD Study (NCT05809908) references GFAP
Tricaprilin Phase 3 ALTER-AD Study (NCT05809908) references GLUT3

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.